Form 4: Intellia Therapeutics EVP, CFO Glenn Goddard, Reports Stock and Option Transactions

Glenn Goddard, EVP and CFO of Intellia Therapeutics, reports acquisition of restricted stock units and stock options, and disposal of common stock.

Summary

• On March 1, 2024, Glenn Goddard, the EVP and Chief Financial Officer of Intellia Therapeutics, acquired 28,628 shares of common stock and 41,316 stock options.
• The stock options have an exercise price of $32.66 and expire on February 28, 2034.
• 33% of the options vest on January 1, 2025, with the remaining 67% vesting in 24 equal monthly installments thereafter.
• Mr. Goddard also disposed of 28,628 shares of common stock.
• Following these transactions, Mr. Goddard directly owns 69,213 shares of Intellia Therapeutics common stock and 41,316 stock options.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither particularly positive nor negative.

Positives

• The grant of stock options and restricted stock units to a key executive like the CFO can be seen as a positive sign, aligning their interests with the company's long-term success.

Negatives

• The disposal of 28,628 shares of common stock by the CFO could be interpreted negatively by some investors, although it may be part of a pre-planned strategy.

Risks

• Executive stock disposals can sometimes signal a lack of confidence in the company's future performance, although this is not always the case.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management's interests with shareholders.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedule of the options (33% on January 1, 2025, and the remaining 67% over 24 months) is a fairly standard vesting arrangement.

Stakeholder Impact

• Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company.

Key Dates